Romosozumab Versus Alendronate and Fracture Risk in Women With Osteoporosis

N Engl J Med. 2018 Jan 11;378(2):195-196. doi: 10.1056/NEJMc1714810.

Publication types

  • Letter
  • Comment

MeSH terms

  • Alendronate*
  • Antibodies, Monoclonal
  • Bone Density
  • Bone Density Conservation Agents
  • Female
  • Fractures, Bone
  • Humans
  • Osteoporosis*
  • Osteoporosis, Postmenopausal

Substances

  • Antibodies, Monoclonal
  • Bone Density Conservation Agents
  • romosozumab
  • Alendronate